We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ionis Pharmaceuticals Inc | NASDAQ:IONS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0 | - |
|
||
(Commission File No.)
|
(IRS Employer Identification No.)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
|
|
Item 1.01 |
Entry into a Material Definitive Agreement.
|
Item 9.01. |
Financial Statements and Exhibits.
|
Exhibit No.
|
Description
|
Press Release dated June 18, 2024. | |
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
Ionis Pharmaceuticals, Inc.
|
||
Dated: June 18, 2024
|
By:
|
/s/ Patrick R. O’Neil |
|
Patrick R. O’Neil
|
|
|
Executive Vice President, Chief Legal Officer and General Counsel
|
• |
Otsuka will be responsible for commercialization efforts for donidalorsen across both Asia Pacific and Europe
|
• |
Ionis plans to independently bring donidalorsen to U.S. patients, if approved
|
Document and Entity Information |
Jun. 18, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Jun. 18, 2024 |
Entity File Number | 000-19125 |
Entity Registrant Name | IONIS PHARMACEUTICALS, INC. |
Entity Central Index Key | 0000874015 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 33-0336973 |
Entity Address, Address Line One | 2855 Gazelle Court |
Entity Address, City or Town | Carlsbad |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92010 |
City Area Code | 760 |
Local Phone Number | 931-9200 |
Title of 12(b) Security | Common Stock, $.001 Par Value |
Trading Symbol | “IONS” |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
1 Year Ionis Pharmaceuticals Chart |
1 Month Ionis Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions